Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-inflammatory Status in DM2 Treated Patients
NCT04392557Phase 4Unknown
- Sponsor
- University of Magna Graecia
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of alogliptin and pioglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by University of Magna Graecia. Primary endpoints: Inflammatory miRNA at 12 months and Side effects at 12 months. Status: unknown.
02
Drugs
alogliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04392557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392557.